High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
PDF | HTML | How to cite
Metrics: PDF 880 views | HTML 1705 views | ?
Ana Koren1, Matija Rijavec1, Eva Sodja1, Izidor Kern1, Aleksander Sadikov2, Viljem Kovac3, Peter Korosec1, Tanja Cufer1
1University Clinic Golnik, Golnik, Slovenia
2University of Ljubljana, Faculty of Computer and Information Science, Ljubljana, Slovenia
3Institute of Oncology Ljubljana, Ljubljana, Slovenia
Ana Koren, email: [email protected]
Keywords: non-small cell lung cancer, peripheral whole blood, BMI1, mRNA expression, prognosis
Received: August 26, 2016 Accepted: February 07, 2017 Published: March 06, 2017
Polycomb group member protein BMI1 is involved in maintaining cell identity, proliferation, differentiation and human oncogenesis. In the present study, we determined BMI1 mRNA expression in whole blood and evaluated the impact of the expression level on the treatment response and survival of 96 advanced NSCLC patients treated with first-line platinum-based chemotherapy. We also determined BMI1 mRNA expression in primary tumors from 22 operable NSCLC patients treated with radical surgery. We found that compared with control subjects, BMI1 mRNA expression in whole blood of advanced NSCLC patients was decreased (P<0.001). Similarly, we observed decreased BMI1 mRNA expression in primary tumors compared to normal lungs from operable NSCLC patients (P=0.001). We found high BMI1 mRNA expression in blood was associated with longer progression-free survival (PFS) (P=0.049) and overall survival (OS) (P=0.012) in advanced NSCLC patients treated with first-line platinum-based chemotherapy. However, no association between the BMI1 mRNA level and response to chemotherapy was found (P=0.21). Multivariate Cox proportional hazards regression analysis showed elevated BMI1 mRNA level in whole blood was an independent prognostic factor for longer PFS (P=0.012) and OS (P<0.001). In conclusion, BMI1 mRNA expression in whole blood might represent a new biomarker for the diagnosis and prognosis of NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.